<DOC>
	<DOCNO>NCT02126371</DOCNO>
	<brief_summary>LEO 32731 ( `` Study Drug '' ) investigational drug develop LEO Pharma A/S ( `` Sponsor '' ) , aim help people skin condition call psoriasis . The aim ( ) Study determine : - The effect Study Drug give different formulation intend oral administration ( tablet capsule ) - The safety Study Drug side effect might associate - The effect food Study Drug - The Study also measure much Study Drug get blood stream long take body remove affect Study Drug body .</brief_summary>
	<brief_title>LP0058-1005 - A Open-Label , Four-Way Crossover Food-Effect Study LEO 32731 Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<criteria>1 . Subjects males ethnic origin 18 55 year age 2 . Subjects body mass index ( BMI ) 18.0 30.0 kg/m2 inclusive 3 . Subjects must good health , determine : medical history , physical examination , vital sign assessment , 12lead electrocardiogram ( ECG ) clinical laboratory evaluation ( congenital non haemolytic hyperbilirubinaemia NOT acceptable ) 4 . Subjects give write informed consent participate study abide study restriction 1 . Male subject willing , whose partner willing , use appropriate contraception ( condom spermicidal foam/gel/film/cream/suppository ) , donate sperm time first dose 3 month final dosing occasion . Male subject whose partner childbearing potential must also agree use additional highly effective method contraception 2 . Subjects abnormality heart rate , blood pressure , temperature respiration rate , opinion investigator , increase risk participate study , accordance Covance current reference range screen confirm repeat assessment . 3 . Subjects abnormality 12lead ECG , opinion investigator , increase risk participate study , confirm repeat ECG : QTcB interval &gt; 450 msec , 2nd 3rd degree , Atrioventricular block , complete leave bundle branch block , complete right bundle branch block , WolffParkinsonWhite Syndrome , define PR &lt; 110 msec , 4 . Subjects receive : prescribe systemic topical medication within 14 day first dose administration unless opinion Investigator medication interfere study procedure compromise safety . slow release medicinal formulation consider still active within 14 day first dose administration , unless opinion Investigator , medication interfere study procedure compromise safety . 5 . Subjects still participate clinical study ( e.g . attend followup visit ) participate clinical study involve administration investigational drug ( new chemical entity ) past 3 month prior first dose occasion 6 . Subjects significant history drug allergy determine Investigator . 7 . Subjects clinically significant allergic disease ( exclude nonactive hayfever ) determine Investigator . 8 . Subjects , history , clinically significant neurological , gastrointestinal , renal , hepatic , cardiovascular , psychiatric , respiratory , metabolic , endocrine , haematological major disorder determine Investigator . 9 . Subjects : know serum hepatitis , carrier hepatitis B surface antigen ( HBsAg ) carrier hepatitis C antibody , positive result test HIV antibody , history active tuberculosis history incompletely treat tuberculosis within last 5 year , confirm medical record</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>